

## DAFTAR PUSTAKA

1. Perhimpunan Dokter Paru Indonesia. Deteksi dini hipertensi pulmonal. Jakarta: 2018.
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. *Am J Respir Crit Care Med*. 2006; 173: 1023–30.
3. Prins K, Thenappan T. World Health Organization group I pulmonary hypertension: epidemiology and pathophysiology. *Cardiol Clin*. 2016; 34: 363–374.
4. Benza R, Gomberg M, Miller D, Frost A, Frantz R, Foreman A, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest*. 2012; 141: 354–362.
5. Arvanitaki A, Boutsikou M, Anthi A, Apostolopoulou S, Avgeropoulou A, Demerouti E, et al. Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). *Pulmonary Circulation*. 2019; 9: 1–12.
6. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman diagnosis dan tatalaksana hipertensi pulmonal. Jakarta: 2021.
7. Wang L, Lee K, Lin C, Hsu L, Wang C, Hsu T, et al. Long-term survival of patients with pulmonary arterial hypertension at a single center in Taiwan. *Acta Cardiologica Sinica*. 2017; 33: 498– 509.
8. Galie N, Ghofrani H, Torbicki A, Barst R, Rubin L, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*. 2006; 354: 1091–3.
9. Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. *J Chiropr Med*. 2006 Autumn;5(3):101-17.
10. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. *Eur Respir J*. 2019 Jan 24;53(1):1801916.
11. Iudici M, Allali D, Porcher R. Correspondence on haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. *BMJ*. 2023 Mar;82(3).

12. Fox DJ, Khattar RS. Pulmonary arterial hypertension: classification, diagnosis and contemporary management. *Postgrad Med J*. 2006 Nov;82(973):717-22.
13. Maron BA, Brittain EL, Choudhary G, Gladwin MT. Redefining pulmonary hypertension. *Lancet Respir Med*. 2018; 6:168–170.
14. Papierniak ES, Lowenthal DT, Mubarak K. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. *Am J Ther*. 2012 Jul;19(4):300-14
15. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, et al. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54:S32–S42.
16. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE. Heterozygous germline mutations in *bmpr2*, encoding a  $\text{tgf-}\beta$  receptor, cause familial primary pulmonary hypertension. *Nat Genet*. 2000;26:81–84.
17. Harrison RE, Flanagan JA, Sankelo M, Abdalla S, Rowell J, Machado RD, et al. Molecular and functional analysis identifies *alk-1* as the predominant cause of pulmonary hypertension related to hereditary hemorrhagic telangiectasia. *J Med Genet*. 2003;40:865–871.
18. Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. *BMJ*. 2004;59:446–448.
19. Aldred MA, Vijaykrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, et al. *Bmpr2* gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. *Human Mutation*. 2006;27:212–213.
20. Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM, Hedges LK, et al. High frequency of *bmpr2* exonic deletions/duplications in familial pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174:590–598.
21. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62:D34–D41.
22. Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. *Clin Chest Med*. 2007;28:43–57.
23. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54:S20–S31.

24. Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C, Stanton KC, et al. Truncating and missense *bmpr2* mutations differentially affect the severity of heritable pulmonary arterial hypertension. *Respir Res.* 2009;10:87.
25. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2012;186:892–896.
26. Harutyunova S, Nagel C, Grünig E, Egenlauf B. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. *Respir Res.* 2020 May 24;21(1):127.
27. Tuder RM, Archer SL, Dorfmueller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol.* 2013;62:D4–D12.
28. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. *Circulation.* 2004;109:159–165.
29. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. *N Engl J Med.* 1995;333:214–221.
30. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, et al. Persistent enos activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through p<sub>gk</sub> nitration. *J Clin Investig.* 2009;119:2009–2018.
31. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. *Arterioscler Thromb Vasc Biol.* 2004;24:413–420.
32. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med.* 1992;327:70–75.
33. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. *Am J Respir Crit Care Med.* 2001;164:314–318.
34. Tuder RM, Cool CD, Geraci MW, Wang J, Abman S, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. *Am J Respir Crit Care Med.* 1999;159:1925–1932.

35. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988;332:411–415.
36. Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. *Free Radic Biol Med*. 2012;52:1970–1986.
37. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med*. 1993;328:1732–1739.
38. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?. *Ann Intern Med* . 1991;114:464–469.
39. Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. *Diseases*. 2018 May 16;6(2):38.
40. Khassafi F, Chelladurai P, Nayakanti S, Martineau S, Tello K, Sommer N, et al. Transcriptional Profiling Unveils New Molecular Subgroups of Adaptive and Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension. *Circulation*. 2022.
41. Furukawa K, Yano M, Ishii H, Sakaguchi S, Mori K, Nishimura M, et al. Influence of preoperative right ventricular function on left ventricular remodeling and survival after subvalvular repair for functional mitral regurgitation. *Heart Vessels*. 2021 Jul;36(7):1064-1071.
42. Furukawa K, Yano M, Ishii H, Sakaguchi S, Mori K, Nishimura M, et al. Clinical Outcomes of a Customized Mitral Valve Plasty for Functional Mitral Regurgitation with a Low Ejection Fraction and Implications for Preoperative Right Ventricular Function. *Ann Thorac Cardiovasc Surg*. 2021 Feb 20;27(1):32-40.
43. Ahmadi A, Renaud JM, Promislow S, Burwash IG, Dwivedi G, Klein R, et al. Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients. *J Nucl Cardiol*. 2021 Dec;28(6):2784-2795.
44. Havlenova T, Skaroupkova P, Miklovic M, Behounek M, Chmel M, Jarkovska D, et al. Right versus left ventricular remodeling in heart failure due to chronic volume overload. *Sci Rep*. 2021 Aug 24;11(1):17136.
45. Wang H, Xu L, Chow K, Pagano JJ, Schmidt A, White JA, et al. Right ventricular remodeling and dysfunction among the spectrum of heart failure phenotypes. *J Cardiovasc Magn Reson*. 2016 Jan 27;18.

46. Hansmann G, Rich S, Maron BA. Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. *Cardiovasc Diagn Ther.* 2020 Oct;10(5):1718-1724.
47. Fox DJ, Khattar RS. Pulmonary arterial hypertension: classification, diagnosis and contemporary management. *Postgrad Med J.* 2006 Nov;82(973):717-22.
48. Currie B, Davies E, Beaudet A, Stassek L, Kleinman L. Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study. *J Patient Rep Outcomes.* 2021 Jun 29;5(1):51.
49. Forfia PR, Trow TK. Diagnosis of pulmonary arterial hypertension. *Clin Chest Med.* 2013 Dec;34(4):665-81.
50. Hansmann G, Rich S, Maron BA. Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. *Cardiovasc Diagn Ther.* 2020 Oct;10(5):1718-1724.
51. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest.* 2004 Jul;126: 14-34.
52. Giusca S, Popa E, Amzulescu MS, Ghiorghiu I, Coman IM, Popescu BA, et al. Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study. *Echocardiography.* 2016 Apr;33(4):546-54.
53. Wang Y, Guo D, Liu M, Zhang X, Hu H, Yang H, et al. Assessment of right ventricular remodeling in chronic thromboembolic pulmonary hypertension by 2D-speckle tracking echocardiography: A comparison with cardiac magnetic resonance. *Front Cardiovasc Med.* 2022 Nov 17; 9:999389.
54. Ryo K, Goda A, Onishi T, Delgado-Montero A, Tayal B, Champion HC, et al. Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography. *Circ Cardiovasc Imaging.* 2015 Jun;8(6):003176.
55. Kocken JMM, Costa Martins PA. Epigenetic regulation of pulmonary arterial hypertension-Induced vascular and right ventricular remodeling: new opportunities ?. *Int J Mol Sci.* 2020 Nov 24;21(23):8901.
56. Bernardo RJ, Haddad F, Couture EJ, Hansmann G, Perez VA, Denault AY, et al. Mechanics of right ventricular dysfunction in pulmonary arterial

hypertension and heart failure with preserved ejection fraction. *Cardiovasc Diagn Ther.* 2020 Oct;10(5):1580-1603.

57. Ma H, Ye P, Zhang AK, Yu WD, Lin S, Zheng YG. Upregulation of miR-335-5p contributes to right ventricular remodeling via calumenin in pulmonary arterial hypertension. *Biomed Res Int.* 2022 Oct 4; 2022:9294148.
58. Goh ZM, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman AMK, et al. Right ventricular remodeling in pulmonary arterial hypertension predicts treatment response. *Heart.* 2022 Aug 11;108(17):1392-1400.
59. Sharifi Kia D, Kim K, Simon MA. Current understanding of the right ventricle structure and function in pulmonary arterial hypertension. *Front Physiol.* 2021 May 28; 12:641310.
60. Vonk NA, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. *Eur Respir J.* 2019 Jan 24;53(1):1801900.
61. Lluçia-Valldeperas A, Man FS, Bogaard HJ. Adaptation and maladaptation of the right ventricle in pulmonary vascular diseases. *Clin Chest Med.* 2021 Mar;42(1):179-194.
62. Wang Z, Patel JR, Schreier DA, Hacker TA, Moss RL, Chesler NC. Organ-level right ventricular dysfunction with preserved Frank-Starling mechanism in a mouse model of pulmonary arterial hypertension. *J Appl Physiol.* 2018 May 1;124(5):1244-1253.
63. Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. *Cardiovasc Diagn Ther.* 2020 Oct;10(5):1522-1540.
64. Shults NV, Kanovka SS, Ten Eyck JE, Rybka V, Suzuki YJ. Ultrastructural changes of the right ventricular myocytes in pulmonary arterial hypertension. *J Am Heart Assoc.* 2019 Mar 5;8(5): e011227.
65. Fulton DJR, Li X, Bordan Z, Wang Y, Mahboubi K, Rudic RD, et al. Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. *Antioxid Redox Signal.* 2019 Nov 10;31(14):1053-1069.
66. Yung LM, Yang P, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. *Sci Transl Med.* 2020 May 13;12(543).

67. Zheng YG, Yang T, He JG, Chen G, Liu ZH, Xiong CM, et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol. 2018 Jun;37(6):365-70.

